Letter: Grading of angina pectoris.

TL;DR: This first-in-human study will investigate the safety and feasibility of targeted pre-emptive PE-DCB treatment of LRPs to promote stabilization of vulnerable coronary plaque at risk for developing future adverse events.

TL;DR: This is the first placebo-controlled trial in patients with stable coronary artery disease, which describes not solely antiischemic properties of LDL-cholesterol reduction as other clinical studies have done previously but also supplies evidence for relative antianginal properties when compared to the natural course of the disease over a period of 2 years.

TL;DR: The uni- and multivariate analysis proved that unstable angina was an independent risk factor in restenosis, re-intervention and cardiac events rate, despite perceptible differences in the baseline characteristics.

TL;DR: Patients surviving non-ST-segment-elevation acute coronary syndrome constitute a group of high coronary risk and sudden death risk and are therefore in particular need of adequate and proper rehabilitation and secondary prevention including physical training, which improved the clinical course of the disease.